Related Experiment Video
Updated: Mar 15, 2026

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4
Published on: December 31, 2013
TRPV1: A Target for Rational Drug Design
Vincenzo Carnevale1, Tibor Rohacs2
1Institute for Computational Molecular Science, Temple University, Philadelphia, PA 19122, USA. vincenzo.carnevale@temple.edu.
Abstract:
Transient Receptor Potential Vanilloid 1 (TRPV1) is a non-selective, Ca(2+) permeable cation channel activated by noxious heat, and chemical ligands, such as capsaicin and resiniferatoxin (RTX). Many compounds have been developed that either activate or inhibit TRPV1, but none of them are in routine clinical practice. This review will discuss the rationale for antagonists and agonists of TRPV1 for pain relief and other conditions, and strategies to develop new, better drugs to target this ion channel, using the newly available high-resolution structures.
Insights
Transient Receptor Potential Vanilloid 1 (TRPV1) channels are key targets for pain relief. This review explores TRPV1 antagonists and agonists, discussing strategies for developing improved drugs using new structural data.
Area of Science:
- Molecular biology
- Neuroscience
- Pharmacology
Background:
- Transient Receptor Potential Vanilloid 1 (TRPV1) is a Ca(2+) permeable cation channel activated by heat and chemicals like capsaicin.
- TRPV1 plays a significant role in pain signaling pathways.
- Existing TRPV1-targeting drugs have not reached routine clinical use.
Purpose of the Study:
- To review the therapeutic potential of TRPV1 antagonists and agonists for pain management.
- To discuss strategies for developing novel and improved TRPV1-targeting drugs.
- To leverage recent high-resolution structural data of TRPV1 for drug design.
Main Methods:
- Literature review of existing research on TRPV1.
- Analysis of high-resolution structural data of the TRPV1 channel.
- Discussion of drug development strategies for TRPV1 modulators.
Main Results:
- Numerous compounds targeting TRPV1 have been developed, but none are in widespread clinical use.
- High-resolution structures provide new insights into TRPV1 channel function and drug binding.
- Both antagonists and agonists show potential for therapeutic applications beyond pain.
Conclusions:
- TRPV1 remains a promising target for novel therapeutics.
- Utilizing structural biology is crucial for designing more effective and selective TRPV1 drugs.
- Further research is needed to overcome challenges in clinical translation for TRPV1-based therapies.
Related Concept Videos
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Pharmacogenomics: Identification of New Drug Targets
Quantitative Aspects of Drug-Receptor Interaction
Drug-Receptor Interaction: Antagonist
Antagonists can be classified as competitive or noncompetitive based on their...
Drug Discovery: Overview
Principles of Drug Action
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...

